Abstract: The invention relates to a collection of signature peptides representing at least 10 proteins for use in cancer diagnosis and/or prognosis, to an artificial protein comprising signature peptides representing at least 10 proteins and to a nucleic acid construct encoding for such an artificial protein. The invention further relates to a collection of at least 10 proteins for use in cancer diagnosis and/or prognosis. Additionally, the invention relates to a method for cancer diagnosis and/or prognosis comprising the step of analyzing at least 10 proteins in a urine sample of a subject. Finally, the invention relates to an immunoassay product comprising antibodies for detecting at least 10 proteins.
Type:
Grant
Filed:
December 23, 2016
Date of Patent:
December 27, 2022
Assignees:
POLYQUANT GMBH, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS, LUXEMBOURG INSTITUTE OF HEALTH, INSTITUT CURIE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III, CNIO
Abstract: The invention describes new compounds derived from formula I pyrroles, methods for obtaining them and their application as drugs in pharmaceutical compositions for the treatment of cancer due to their inhibitory activity on certain histone deacetylases.
Type:
Grant
Filed:
December 27, 2005
Date of Patent:
December 29, 2009
Assignee:
Universidad del Pais Vasco-Euskal Herriko Unibertsitatea (UPV-EHU) Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO)
Inventors:
Fernando Pedro Cossio Mora, Manel Esteller Badosa, Aizpea Zubia Olascoaga, Dorleta Otaegui Ansa